Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer

Breast cancer alone accounts for the majority of cancer deaths among women, with the most commonly diagnosed subtype being estrogen receptor positive (ER+). Survival has greatly improved for patients with ER+ breast cancer, due in part to the development of antiestrogen compounds, such as tamoxifen....

Full description

Bibliographic Details
Main Authors: Emily K. Zboril, Jacqueline M. Grible, David C. Boyd, Nicole S. Hairr, Tess J. Leftwich, Madelyn F. Esquivel, Alex K. Duong, Scott A. Turner, Andrea Ferreira-Gonzalez, Amy L. Olex, Carol A. Sartorius, Mikhail G. Dozmorov, J. Chuck Harrell
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
estrogen receptor
ER+ breast cancer
tamoxifen
endocrine resistance
drug synergism
patient-derived xenograft
Online Access:https://www.mdpi.com/2072-6694/15/12/3179

Similar Items

Similar Items